International Journal of Healthcare Sciences ISSN 2348-5728 (Online)
Vol. 4, Issue 2, pp: (972-977), Month: October 2016 - March 2017, Available at: www.researchpublish.com

Overview of Prevention and Management of Rh Alloimmunization in Pregnancy

[1]Enas elsayed sharaf Khalil, [2]Ahmed reyad elrify, [3]Emad mohammed ghafori, [4]Tariq faruk kurdi

Abstract: **Maternal alloimmunization, likewise referred to as isoimmunization, happens when a lady's body immune system is sensitized to foreign erythrocyte surface area antigens, stimulating the production of immunoglobulin G (IgG) antibodies. We aimed by this review to emphasize the important and procedures which are done to prevent and to manage the Rh alloimmunization in pregnancy, we also aimed to discuss the complications that can occur in relation to this condition. The Embase and MEDLINE databases were searched for English-language articles to November 2016, relating to the prevention of Rh alloimmunization. Searching done using following terms: "Rho(D) immune globulin", "Rh iso- or allo-immunization", "anti-D, anti-Rh" together with other secondary terms which are: "pregnancy" and "prevention" and "Treatment". Many scientific scenarios showed that the several factors can cause a Rh D-negative female to become alloimmunized. Of Rh D-negative women who do not receive RhoGAM during pregnancy, 17% will become alloimmunized; 90% of these cases can result from fetomaternal hemorrhage at delivery; 10% can arise from antenatal fetomaternal hemorrhage. Other evidence from our review stated that the quantity of blood had to become alloimmunized is tiny; a fetomaternal hemorrhage of less than 0.1 mL is all that is needed. Decreased incidence of Rh alloimmunization and decreased practice variation with regards to immunoprophylaxis strategies.**

Keywords: **alloimmunization, immunoprophylaxis, "Rho (D) immune globulin", RhoGAM.**

1. INTRODUCTION

Maternal alloimmunization, likewise referred to as isoimmunization, happens when a lady's body immune system is sensitized to foreign erythrocyte surface area antigens, stimulating the production of immunoglobulin G (IgG) antibodies [(1)]. Evaluation of maternal ABO blood group, Rh type and anti D antibodies (indirect Coombs test) should found at every first prenatal see [(1)]. Ladies who are Rh D unfavorable with a favorable anti D antibody screen test are thought about Rh alloimmunized [(2,3)]. The assessment of fetal Rh D status ought to be done to determining if the pregnancy is at risk for the advancement of hemolytic disease of the fetus and newborn. In fact, if the fetus is Rh D-negative doesn't need any intervention irrespective of maternal antibodies titers. If the daddy is Rh D unfavorable the fetus is likewise Rh D unfavorable when paternity is certain. If the father is Rh D favorable, he can be either heterozygous or homozygous for the D allele. The fetus is Rh D positive [(4,5)] if he is homozygous for the D allele.

The most common paths of maternal sensitization are by means of blood transfusion or fetomaternal hemorrhage (ie, transplacental passage of fetal erythrocytes) associated with delivery, trauma, induced or spontaneous abortion, ectopic pregnancy, or invasive obstetric treatments [(6)]. These antibodies can cross the placenta during pregnancies in alloimmunized females and, if the fetus is positive for these specific erythrocyte surface area antigens, result in hemolysis of fetal erythrocytes and anemia. This, in turn, can cause possibly disastrous effects for the fetus, such as hydrops fetalis (seen below), a high-output heart failure syndrome. With the institution of antenatal Rhesus (Rh) D immunoglobulin prophylaxis, the frequency of maternal alloimmunization in Rh D-- negative women has actually decreased substantially [(7)].

Anti-D immunoprophylaxis has made erythroblastosis fetalis caused by sensitization to the D-antigen a preventable disease, and perinatal deaths from alloimmunization have fallen 100-fold [(8)]. Avoidance of Rh alloimmunization by immunoprophylaxis has actually been mainly responsible for the dramatic decrease in the occurrence of the mortality from this disease, although modifications in family size and the quality of perinatal care have likewise contributed [(9)].

Anti-D IgG has actually been licensed for routine postpartum prophylaxis because 1968 in Canada, and routine antepartum prophylaxis was introduced in 1976 [10]. Maternal alloimmunization still takes place in 0.4 per 1000 births [11,12] or around 1% to 2% of D-negative females in Canada and the United Kingdom, [13,14] typically from failure to administer anti-D immune globulin to qualified pregnant and postpartum females or because of insufficient dosing schedules [15].

- **Objectives:**

We aimed by this review to emphasize the important and procedures which are done to prevent and to manage the Rh alloimmunization in pregnancy, we also aimed to discuss the complications that can occur in relation to this condition.

2. METHODOLOGY

The Embase and MEDLINE databases were searched for English-language articles to November 2016, relating to the prevention of Rh alloimmunization. Searching done using following terms: "Rho(D) immune globulin", "Rh iso- or allo-immunization", "anti-D, anti-Rh" together with other secondary terms which are: "pregnancy" and "prevention" and "Treatment". Additional articles were identified from the bibliographies list of included studies. All study types were reviewed, Randomized controlled trials (RCTs), systematic reviews, and Meta-analysis.

3. RESULTS

Spontaneous abortions are related to a 1.5% to 2% risk of alloimmunization, and healing abortions are associated with a 4% to 5% risk of alloimmunization in Rh D-negative ladies. Threatened abortions, ectopic pregnancies, chorionic villus sampling (CVS), amniocentesis, cordocentesis, blunt abdominal trauma, hydatiform mole, an intrauterine fetal demise in the 3rd or 2nd trimester, and external cephalic variation all have risks of fetomaternal hemorrhage. Therefore, they all can trigger Rh D alloimmunization. Potentially the most substantial risk for numerous Rh D-negative ladies is the risk of spontaneous abortion. Lots of females have miscarriages prior to they even understand that they are pregnant [1,4].

- ***Anti-D immune globulin and its role in treatment of Rh alloimmunization in pregnancy:***

Rhesus (RhO [D] immune globulin (RhIG) is a hyperimmune plasma acquired directed at red cell (RBCs) positive for Rh antigen (also called D antigen) [15]. Alloimmunization to the D antigen is a welldescribed potential outcome of fetomaternal transplacental hemorrhage, which can occur during childbirth or pregnancy in D antigen-- unfavorable (D-negative) ladies who have a D antigen-- favorable (D-positive) fetus. Alloimmunization may lead to hemolytic disease of the fetus and newborn (HDFN) in future pregnancies. If RhIG therapy is instituted in the immediate postexposure duration, alloimmunization can be prevented and the risk of dangerous results of HDFN can be mitigated [16].

Throughout subsequent pregnancies with a D-positive infant, maternal anti-D IgG production takes place quickly and to a higher titer. Unlike IgM antibodies, IgG antibodies efficiently cross the placental barrier. The anti-D antibodies attach to fetal RBCs and lead to severe hemolysis [17] when they get in the fetal flow. Prior to the advent of modern preventive immunotherapies, HDFN led to death due to kernicterus or hydrops fetalis in around 50% of impacted infants. This rate has actually now decreased to less than 1% in industrialized countries [8]. The very first RhIG preparations went into clinical usage in 1968 and minimized the risk of alloimmunization in the mother from 8.9% to less than 1% [19]. Early preparations were derived from entire plasma using Cohn fractionation [20] and, due to impurities inherent in the preparation procedure, frequently led to immunologic reactions such as anaphylaxis [21]. Some current RhIG products are separated from entire plasma using ion-exchange resins, possibly resulting in a greater degree of purity. These items can be administered both intravenously and intramuscularly [22,23]. In addition to their energy in preventing maternal alloimmunization, RhIG products have actually been shown to be efficient in the treatment of idiopathic thrombocytopenic purpura (ITP). These usages are beyond the scope of this post, and readers are directed to two excellent reviews for more details [24,25].

- **Prevention of *Rh alloimmunization during pregnancy:***

Turner et al. [24] performed a predisposition adjusted meta-analysis of offered studies of routine antenatal prophylaxis with RhIG, discovering that prophylaxis was extremely effective at preventing alloimmunization, with a pooled odds ratio for Rh sensitization among treated ladies of 0.31 (95% confidence period [CI], 0.17- 0.56). Extra analyses were carried out in an effort to recognize the most effective dosing scheme. All presently utilized programs were discovered to be efficient; nevertheless, a two-dose (250 mg per dose) method was more likely to be efficient than a single dosage (300 mg) technique. These results contrast with those of a current meta-analysis carried out by the Cochrane Collaboration,45 that included data from 2 randomized trials [25,26].

The meta-analysis showed that antenatal prophylaxis is inefficient in preventing alloimmunization, with a risk ratio of 0.42 (95% CI, 0.15- 1.17) in Untreated versus rhig-treated ladies. Of note, one of the two trials included in the meta-analysis assessed the effectiveness of two 50-mg RhIG dosages, with the authors noting that this dosing method was not as efficient as a single 300-mg dosage [26]. Other events during pregnancy might also cause maternal alloimmunization. Planned and spontaneous abortions present a risk of transplacental hemorrhage of 1.5 - 5%, [27] while chorionic villus tasting is associated with a little degree of hemorrhage in nearly all cases, with potentially sensitizing volumes greater than 0.1 mL in up to one third of cases (28). Other invasive occasions, consisting of amniocentesis, ectopic pregnancy, and stomach trauma during pregnancy, likewise posture a risk [29,30]. Even noninvasive treatments such as external cephalic version (a procedure used to remedy breech presentation) are connected with fetomaternal hemorrhage in as lots of as 6% of cases [31]. There are limited data to guide making use of RhIG prophylaxis in these cases, with a lot of recommendations originating from professional viewpoint [32].

In addition to fetomaternal hemorrhage, inadvertent administration of Rh-incompatible blood products may result in alloimmunization; the offered information to guide treatment techniques in such cases are likewise limited. Pollack et al. [33] (transfused healthy D-negative volunteers with D-positive RBCs and determined that a minimum of 20 mg of RhIG was required to prevent alloimmunization from 1 mL of RBCs. Earlier case reports revealed that the administration of high dosages of RhIG is both well tolerated and efficient in preventing alloimmunization, suggesting that big doses may be appropriate in the event of an enormous transfusion of Rh-incompatible blood items [33].

In the United States, three companies have actually released suggestions on the optimum use of RhIG. Both the American Society of Clinical Pathologists and the United States Preventive Services Taskforce suggest a dosage of 300 mg followed by a postnatal dose if the infant is Rh positive [34,35]. ACOG advises a 50-mg dose for firsttrimester events (due to lower fetal blood volume throughout that duration) and 300 mg for occasions after the very first trimester. In addition, the ACOG guidelines suggest a regular antenatal dose of 300 mg at 28 weeks' pregnancy. A summary of the ACOG suggestions is supplied in (**Table 1**) [34,35].

Table 1: American College of Obstetrics and Gynecology Recommendations for Prevention of Rh-Antigen Alloimmunization [34,35]

Clinical Scenario	**Prophylaxis Recommended?**
Paternity	
Father Rh+, mother Rh–	Yes
Father Rh–, mother Rh–	No
Father unknown, mother Rh–	Yes
Mother Rh+	No
Previously sensitized mother	No
Weakly Rh+ mother	No
Threatened abortion before 12 weeks’	
gestation	No recommendation
1st-trimester event or procedure	Yes (50 µg)
2nd- or 3rd-trimester event or procedure	Yes (300 µg)
Molar pregnancy with uterine evacuation	Yes
Intrauterine fetal demise in 2nd or 3rd	
trimester	Yes (FMHS recommended)
2nd- or 3rd-trimester antenatal hemorrhage	Yes (FMHS recommended)
Abdominal trauma in pregnancy	Yes (FMHS recommended)
Clinically overlooked sensitizing event	Yes (up to 28 days after event)
Postterm pregnancy	No recommendation

aFMHS = fetomaternal hemorrhage screening.

- ***Clinical efficacy of Anti-D immune globulin:***

Regular postnatal administration of RhIG within 72 hours of shipment in ladies with Rh-incompatible pregnancies was adopted quickly after RhIG became consistently available, and the practice considerably reduced the frequency of Rh alloimmunization [(36)]. A Cochrane evaluation of postnatal prophylaxis, carried out utilizing a range of differing dosing methods in over 10,000 ladies, showed the consistency of this effect across treatment groups and dosing strategies, with a relative risk of Rh sensitization of 0.04 with prophylaxis versus no prophylaxis [(37)]. The authors of this meta-analysis concluded that while the optimum dose for postnatal prophylaxis stays uncertain, there is a beneficial trend of improved results with making use of greater dosages, constant with the dose-dependent neutralization effect of RhIG [(18)].

- ***Intrauterine Transfusion in treatment of Rh alloimmunization:***

The intraperitoneal transfusion remained the mainstay of fetal treatment for almost 20 years after its introduction by Liley in 1963 [(38)]. With the development of real-time ultrasound for guidance, direct access to the fetal circulation by puncturing the umbilical cable at its placental insertion ended up being commonplace. As a result, the direct intravascular transfusion has actually changed the intraperitoneal transfusion in many centers. Compared with the intraperitoneal transfusion, the intravascular transfusion is clearly useful to the hydropic fetus where absorption of cells from the peritoneal cavity is compromised. Some centers continue to include the intraperitoneal transfusion through a combined treatment in conjunction with the intravascular transfusion; many European centers choose to utilize the intrahepatic portion of the umbilical vein as the site of intravascular transfusion. The source of red cells for intrauterine transfusion is normally a blood type O, RhD-negative, cytomegalovirus-negative donor. Cells are packed to a hematocrit of 75 - 85% to prevent volume overload. Units are irradiated to prevent graft-versus-host reaction and processed through a leukocyte-poor filter. Some centers prefer to use maternal blood as the source of red cells [(39)].

During the age of intraperitoneal transfusions, fetuses were regularly provided at 32 weeks' gestation and often suffered issues of prematurity such as hyaline membrane disease and the need for neonatal exchange transfusions for the treatment of hyperbilirubinemia. As experience with intravascular transfusion ended up being extensive, pregnancies were provided at later gestational ages. The majority of authorities will now perform the last intrauterine transfusion at up to 35 weeks' pregnancy, with delivery anticipated at 37 - 38 weeks [(40)].

4. CONCLUSION

Many scientific scenarios showed that the several factors can cause a Rh D-negative female to become alloimmunized. Of Rh D-negative women who do not receive RhoGAM during pregnancy, 17% will become alloimmunized; 90% of these cases can result from fetomaternal hemorrhage at delivery; 10% can arise from antenatal fetomaternal hemorrhage. Other evidence from our review stated that the quantity of blood had to become alloimmunized is tiny; a fetomaternal hemorrhage of less than 0.1 mL is all that is needed. Decreased incidence of Rh alloimmunization and decreased practice variation with regards to immunoprophylaxis strategies.

REFERENCES

[1] Fan J, Lee BK, Wikman AT, Johansson S, Reilly M. Associations of Rhesus and non-Rhesus maternal red blood cell alloimmunization with stillbirth and preterm birth. *Int J Epidemiol*. 2014 Aug. 43 (4):1123-31.

[2] Pirelli K, Pietz B, Johnson S, Pinder H, Bellissimo D. Molecular determination of RhD zygosity. Am J Obstet Gynecol. 2006;195:S172.

[3] Lo YM, Hjelm NM, Fidler C, Sargent IL, Murphy MF, Cham-berlain PF, et al. Prenatal diagnosis of fetal RhD status bymolecular analysis of maternal plasma. N Engl J Med. 1998;339:1734–8.

[4] Geifman-Holtzman O, Grotegut CA, Gaughan JP. Diag-nostic accuracy of noninvasive fetal Rh genotyping frommaternal blood–a meta-analysis. . Am J Obstet Gynecol. 2006;195:1163–73.

[5] Brown S, Kellner LH, Munson M, Munson M, Yang Y, Klotzle B, et al. Non-invasive prenatal testing: technical strate-gies to achieve testing of cell free fetal DNA (CFFDNA)RhD genotype in a clinical lab. Am J Obstet Gynecol. 2007;197:S173.

[6] Markham KB, Rossi KQ, Nagaraja HN, O'Shaughnessy RW. Hemolytic disease of the fetus and newborn due to multiple maternal antibodies. Am J Obstet Gynecol. 2015 Jul. 213 (1):68.e1-5.

[7] Bombard AT, Akolekar R, Farkas DH, et al. Fetal RHD genotype detection from circulating cell-free fetal DNA in maternal plasma in non-sensitized RhD negative women. Prenat Diagn. 2011 Aug. 31(8):802-8.

[8] Urbaniak S.The scientific basis of antenatal prophylaxis. Br J Obstet Gynaecol 1998;105:11–8.

[9] Joseph K, Kramer M.The decline of Rh hemolytic disease: should Rh prophylaxis get all the credit? Am J Public Health 1998;88:209–15.

[10] Bowman J, Pollock J. Antenatal prophylaxis of Rh isoimmunization: 28 weeks gestation service programme. Can Med Assoc J 1978;118:627–30.

[11] Armson BA, Parson ML.The Rh program of Nova Scotia 1964–1994. Halifax: Atlantic Society of Obstetricians and Gynaecologists; 1995.

[12] Bowman J, Pollock J. Failures of intravenous Rh immune globulin prophylaxis: an analysis for the reasons of such failures. Transf Med Rev 1987;1:101–12.

[13] Tovey L,Townley A, Stevenson B,Tavener J.The Yorkshire antenatal anti-D immunoglobulin trial in primigravidae. Lancet 1983;2:244–6.

[14] Urbaniak S. Consensus conference on anti-D prophylaxis, April 7 & 8, 1997: final consensus statement of the Royal College of Edinburgh/Royal College of Obstetricians and Gynaecologists. Transfusion 1998;38:97–9.

[15] Ayache S, Herman JH. Prevention of D sensitization after mismatched transfusion of blood components: toward optimal use of RhIG. Transfusion. 2008; 48:1990-9.

[16] Brinc D, Lazarus AH. Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn. Hematology Am Soc Hematol Educ Program. 2009; 185-91.

[17] Liumbruno GM, D'Alessandro A, Rea F et al. The role of antenatal immunoprophylaxis in the prevention of maternal-foetal anti-Rh(D) alloimmunisation. Blood Transfus. 2010; 8:8-16.

[18] Jandl JH, Jones AR, Castle WB. The destruction of red cells by antibodies in man. I. Observations of the sequestration and lysis of red cells altered by immune mechanisms. J Clin Invest. 1957; 36:1428-59.

[19] Bowman JM. The prevention of Rhimmunization. Can Fam Physician. 1977; 23:60-8.

[20] Cohn EJ, Strong LE, Hughes WL et al. Preparation and properties of serum and plasma proteins; a system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc. 1946; 68:459-75.

[21] Bowman JM, Friesen AD, Pollock JM et al. WinRho: Rh immune globulin prepared by ion exchange for intravenous use. Can Med Assoc J. 1980; 123:1121-7.

[22] Okwundu CI, Afolabi BB. Intramuscular versus intravenous anti-D for preventing Rhesus alloimmunization during pregnancy. Cochrane Database Syst Rev. 2013; 1:CD007885.

[23] Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002; 346:995-1008.

[24] Turner RM, Lloyd-Jones M, Anumba DO et al. Routine antenatal anti-D prophylaxis in women who are Rh(D) negative: meta-analyses adjusted for differences in study design and quality. PLoS One. 2012; 7:e30711.

[25] Huchet J, Dallemagne S, Huchet C et al. [Ante-partum administration of preventive treatment of Rh-D immunization in rhesus-negative women. Parallel evaluation of transplacental passage of fetal blood cells. Results of a multicenter study carried out in the Paris region]. J Gynecol Obstet Biol Reprod (Paris). 1987; 16:101- 11.

[26] Lee D, Rawlinson VI. Multicentre trial of antepartum low-dose anti-D immunoglobulin. Transfus Med. 1995; 5:15-9.

[27] Matthews CD, Matthews AE. Transplacental haemorrhage in spontaneous and induced abortion. Lancet. 1969; 1:694-5.

[28] Katiyar R, Kriplani A, Agarwal N et al. Detection of fetomaternal hemorrhage following chorionic villus sampling by Kleihauer Betke test and rise in maternal serum alpha feto protein. Prenat Diagn. 2007; 27:139-42.

[29] Bowman JM. Controversies in Rh prophylaxis. Who needs Rh immune globulin and when should it be given? Am J Obstet Gynecol. 1985; 151:289-94.

[30] Blajchman MA, Maudsley RF, Uchida I et al. Letter: diagnostic amniocentesis and fetal-maternal bleeding. Lancet. 1974; 1:993-4.

[31] Marcus RG, Crewe-Brown H, Krawitz S et al. Feto-maternal haemorrhage following successful and unsuccessful attempts at external cephalic version. Br J Obstet Gynaecol. 1975; 82:578-80.

[32] Karanth L, Jaafar SH, Kanagasabai S et al. Anti-D administration after spontaneous miscarriage for preventing Rhesus alloimmunisation. Cochrane Database Syst Rev. 2013; 3:CD009617.

[33] Pollack W, Ascari WQ, Kochesky RJ et al. Studies on Rh prophylaxis. 1. Relationship between doses of anti-Rh and size of antigenic stimulus. Transfusion. 1971; 11:333-9.

[34] Hartwell EA, for the American Society of Clinical Pathologists. Use of Rh immune globulin: ASCP practice parameter. Am J Clin Pathol. 1998; 110:281-92.

[35] U.S. Preventive Services Task Force. Screening for Rh (D) incompatibility RecommendationStatementFinal/rh-dincompatibility-screening

[36] Ascari WQ, Allen AE, Baker WJ et al. Rh-o (D) immune globulin (human). Evaluation in women at risk of Rh immunization. JAMA. 1968; 205:71-4.

[37] Crowther C, Middleton P. Anti-D administration after childbirth for preventing Rhesus alloimmunisation. Cochrane Database Syst Rev. 2000; 2:CD000021.

[38] Liley AW. Intrauterine transfusion of foetus in haemolytic disease. Br Med J 1963;2:1107–9.

[39] Gonsoulin WJ, Moise KJ Jr, Milam JD, Sala JD, Weber VW, Carpenter RJ Jr. Serial maternal blood donations for intrauterine transfusion. Obstet Gynecol 1990;75:158–62.

[40] Klumper FJ, van Kamp IL, Vandenbussche FP, Meerman RH, Oepkes D, Scherjon SA, et al. Benefits and risks of fetal red-cell transfusion after 32 weeks gestation. Eur J Obstet Gynaecol Reprod Biol 2000;92:91–6.